Neuronetics (STIM) Aktie Kurs
Neuronetics Kurs
Under de senaste 9 åren växte Neuronetics intäkterna med 17,8 % årligen och nådde 149,16 M USD. För Neuronetics är nettovinstmarginal på −26,1 % upp jämfört med −56,4 % för några år sedan. Det konsensusbaserade 12-månaderskursmålet för Neuronetics är 5,00 USD, cirka över kursen med 249,7 %. Av 10 analytiker ger 9 köpråd — den samlade bedömningen är Köp.
Neuronetics aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
Neuronetics affärsmodell och aktieanalys
Vanliga frågor om Neuronetics-aktien
The business model of Neuronetics Inc. focuses on providing innovative medical technology solutions for patients suffering from psychiatric disorders, particularly major depressive disorder (MDD). As a leading medical device company, Neuronetics specializes in developing and commercializing NeuroStar® Advanced Therapy, an FDA-cleared non-invasive transcranial magnetic stimulation (TMS) system. This breakthrough treatment option offers a safe and effective alternative to traditional antidepressant medications. Neuronetics offers a comprehensive approach, combining their advanced TMS technology with clinical support and patient education. By addressing the unmet needs of individuals with MDD, Neuronetics aims to improve the quality of life for patients and enhance mental health treatment outcomes.
Neuronetics Inc is primarily active in the healthcare industry.
The main competitors of Neuronetics Inc in the market include companies such as MagVenture, BrainsWay, and Fisher Wallace.
Neuronetics Inc is a reputable medical device company founded in 2003. Headquartered in Pennsylvania, the company focuses on developing innovative treatments for psychiatric disorders, specifically major depressive disorder (MDD). Neuronetics Inc is widely recognized for its groundbreaking invention, NeuroStar Advanced Therapy system, which utilizes transcranial magnetic stimulation (TMS) to alleviate depressive symptoms. With a commitment to providing non-invasive and effective solutions, Neuronetics Inc has gained significant recognition within the medical community. Over the years, the company has strived to improve patients' well-being and enhance mental health treatment options, solidifying its position as a leader in the field of neuromodulation therapies.
Neuronetics Inc has achieved significant milestones since its inception. The company introduced the NeuroStar Advanced Therapy, an FDA-cleared transcranial magnetic stimulation (TMS) system, which has revolutionized the treatment of depression. Neuronetics Inc expanded its reach by attaining various regulatory clearances globally, allowing patients worldwide to benefit from TMS therapy. The company also secured multiple strategic partnerships, further enhancing its market presence and advancing the field of neuromodulation. Neuronetics Inc's dedication to research and innovation has led to numerous clinical publications highlighting the effectiveness of NeuroStar TMS therapy. With its relentless pursuit of advancing psychiatric care, Neuronetics Inc continues to make significant strides in improving patient outcomes and quality of life.
Neuronetics Inc is primarily present in the United States.
Neuronetics Inc represents values of innovation, patient-centricity, and continuous improvement. With a corporate philosophy focused on developing advanced solutions for mental health disorders, Neuronetics Inc strives to improve the lives of individuals suffering from depression. The company's NeuroStar Advanced Therapy system, utilizing transcranial magnetic stimulation, is a testament to their commitment to innovation and providing effective treatment options. By placing patients at the center of their efforts, Neuronetics Inc aims to enhance mental health outcomes and restore hope for those in need.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 5,00 USD för Neuronetics-aktien (median: 5,00 USD), vilket innebär +249,7 % mot senaste kurs. Konsensus baseras på 10 analytikerbetyg.
10 analytiker betygsätter för närvarande Neuronetics-aktien: 9 rekommenderar köp, 1 behåll och 0 sälj. För 2026 väntar sig analytiker att Neuronetics genererar intäkter på 162,29 M USD och vinst per aktie på −0,28 USD.
Omräknat till aktuell växelkurs handlas Neuronetics-aktien till 1,29 EUR (1,43 USD).
Neuronetics-aktien (STIM) är noterad på 3 börser, bland annat: NASDAQ (STIM), Frankfurt (NRC.F), München (NRC.MU).
Neuronetics Inc. is a leading manufacturer of medical devices that help patients with mental disorders such as depression. The company is headquartered in Malvern, Pennsylvania, USA. Neuronetics Inc.'s business model is based on selling devices for Transcranial Magnetic Stimulation (TMS). TMS is a non-invasive method for treating severe depression in patients who have not responded to other treatment methods. The method uses high-intensity magnetic pulses to stimulate the brain, resulting in a reduction of symptoms. The company's core product is the NeuroStar Advanced Therapy System (ATS). The system consists of a TMS device and a specialized treatment chair. The chair can be individually adjusted to meet the patient's needs for optimal treatment. The NeuroStar ATS is the first TMS therapy in the USA to be approved by the Food and Drug Administration (FDA) for use in patients with depression. Neuronetics Inc. distributes its products through a broad sales structure. The company has its own sales representatives who handle the sales and marketing of the products in the USA and Europe. In addition, Neuronetics Inc. collaborates with distribution partners to distribute its products in countries where the company is not directly represented. The company also has a strong research component. Neuronetics Inc. has established a network of clinics and research institutions that participate in clinical studies on TMS therapy. The company also supports independent researchers working on the development of new applications of TMS therapy. Neuronetics Inc. works closely with health insurance companies and private insurers to ensure that its products can be used by as many patients as possible. The company maintains constant contact with healthcare decision-makers and organizes regular conferences and workshops to inform about the possibilities of TMS therapy. In summary, Neuronetics Inc. is an innovative company dedicated to the treatment of patients with severe depression. The company offers a high-quality and safe treatment system that has already been successfully used by many patients. With its broad sales structure and strong research component, Neuronetics Inc. is well positioned to continue to play a leading role in the market for TMS therapy.
Omsättningen för förväntad Neuronetics är 162,29 M USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för förväntad Neuronetics är −19,25 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Neuronetics är för närvarande −5,11. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Neuronetics-aktien.
Kurs-försäljningskvoten (P/S) för Neuronetics är för närvarande 0,61. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Neuronetics-aktien.
Eulerpool Quality Score för Neuronetics är 3/10.
ISIN för Neuronetics är US64131A1051. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Neuronetics är A2JPMY. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Neuronetics är STIM. Tickersymbolen används för att handla Neuronetics-aktier på börsen.
Neuronetics aktie
Neuronetics Jämförbar grupp
Neuronetics Ticker
Neuronetics FIGI
Alla nyckeltal och djupgående analys av Neuronetics
Vår aktieanalys av Neuronetics-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Neuronetics. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: